Lise J. Estcourt

Lise J. Estcourt

Auto-generated profile, based on publicly available information

Lise J. Estcourt

Radcliffe Department of Medicine; University of Oxford; Oxford UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2016 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LELise J. Estcourt
Lise J. Estcourt
JBJanet Birchall
Janet Birchall
SAShubha Allard
Shubha Allard
SBStephen J. Bassey
Stephen J. Bassey
PHPeter Hersey
Peter Hersey
THthe British Committee for Standards in Haematology
the British Committee for Standards in Haematology

9 May 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
SSSimon J. Stanworth
Simon J. Stanworth
LELise J. Estcourt
Lise J. Estcourt
GPGillian Powter
Gillian Powter
BKBrennan C. Kahan
Brennan C. Kahan
CDClaire Dyer
Claire Dyer
MMMichael F. Murphy
Michael F. Murphy
The effectiveness of platelet transfusions to prevent bleeding in patients with hematologic cancers remains unclear. This trial assessed whether a policy of not giving prophylactic platelet transfusions was as effective and safe as a policy of providing prophylaxis.

1 March 2018 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
HHHarriet Hunt
Harriet Hunt
APAlex Pollock
Alex Pollock
PCPauline Campbell
Pauline Campbell
LELise Estcourt
Lise Estcourt
GBGinny Brunton
Ginny Brunton
Overviews of systematic reviews are a relatively new approach to synthesising evidence, and research methods and associated guidance are developing. Within this paper we aim to help readers understand key issues which are essential to consider when taking the first steps in planning an overview. These issues relate to the development of clear, relevant research questions and objectives prior to the development of an overview protocol. Initial discussions and key concepts for this paper were formed during a workshop on overview methods at the 2016 UK Cochrane Symposium, at which all members of this author group presented work and contributed to wider discussions. Detailed descriptions of the various key features of overviews and their different objectives were created by the author group based upon current evidence (Higgins J, Green S. Cochrane Handbook Syst Rev Interv. 2011;4:5, Pollock M, et al. Sys Rev. 2016;5:190-205, Pollock A, et al. Cochrane overviews of reviews: exploring the methods and challenges. UK and Ireland: Cochrane Symposium; 2016, Pieper D, et al. Res Syn Meth. 2014;5:187–99, Lunny C, et al. Sys Rev. 2016;5:4-12, Hartling L, et al. Comparing multiple treatments: an introduction to overviews of reviews. In 23rd Cochrane Colloquium; 2015, Hartling L, et al. Plos One. 2012;7:1-8, Ballard M, Montgomery P. Res Syn Meth. 2017;8:92-108) and author experiences conducting overviews. Within this paper we introduce different types of overviews and suggest common research questions addressed by these overviews. We briefly reflect on the key features and objectives of the example overviews discussed. Clear decisions relating to the research questions and objectives are a fundamental first step during the initial planning stages for an overview. Key stakeholders should be involved at the earliest opportunity to ensure that the planned overview is relevant and meaningful to the potential end users of the overview. Following best practice in common with other forms of systematic evidence synthesis, an overview protocol should be published, ensuring transparency and reducing opportunities for introduction of bias in the conduct of the overview.

20 July 2015 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SSSimon J. Stanworth
Simon J. Stanworth
CNCristina Navarrete
Cristina Navarrete
LELise Estcourt
Lise Estcourt
JMJudith Marsh
Judith Marsh

4 October 2021 in JAMA
Verified
Journal Article
Open access
PDF file
HAHesham Abdelhady
Hesham Abdelhady
MAMarwa Abdelrazik
Marwa Abdelrazik
ZAZakee Abdi
Zakee Abdi
DADavid Abdo
David Abdo
AAAmina Abdulle
Amina Abdulle
DRDavid J. Roberts
David J. Roberts
COVID-19 is an acute illness caused by SARS-CoV-2.1 Among the many treatments studied,2 only 2 immunomodulatory drugs, glucocorticoids and IL-6 receptor antagonists,3,4 have been shown to reduce mortality in hospitalized adults with COVID-19; and critically ill patients have shown greater benefit with glucocorticoids.5 Convalescent plasma (blood product containing SARS-CoV-2–specific antibodies) is a biologically plausible antiviral treatment with immunomodulatory properties6-9 that may offer greater benefit to critically ill patients with COVID-19, in whom multiorgan dysfunction could be driven by the higher prevalence of SARS-CoV-2 RNA in blood, also known as RNAemia, and by progressive host response.10,11 However, use of convalescent plasma for patients with COVID-19 has either been outside clinical trials, with more than 500 000 patients estimated to have received this treatment in the US by March 2021,12 or in randomized clinical trials that have not focused on critically ill patients with COVID-19, often without improving clinical outcomes, including in the recently published Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial.13-15

12 October 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
KCKhai Li Chai
Khai Li Chai
SVSarah J Valk
Sarah J Valk
VPVanessa Piechotta
Vanessa Piechotta
CKCatherine Kimber
Catherine Kimber
IMIna Monsef
Ina Monsef
NSNicole Skoetz
Nicole Skoetz